When CML patients were dichotomized in “low” and “high” expression groups and a contingency analysis was performed, as explained above, the observed proportions for the low and high expression groups showed significant difference among the CML phases, with the high expression of MLL3/KMT2C being more frequent in the chronic phase (Fig. 2b, Chi square goodness of fit test, p = 0.0212). Here, KMT2C is linked to chronic myelogenous leukemia, BCR-ABL1 positive.